The Company's lead product candidate is cenicriviroc, (formerly TBR-652), a potent antagonist of both CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor that is prominently involved in a number of metabolic and cardiovascular diseases.

In 2010, Tobira announced Phase lla results, demonstrating potent antiviral and anti-inflammatory activity in treatment-experienced HIV patients. Potential for once-daily dosing, co-formulation with other antiretrovirals, such as nucleoside-sparing or ritonavir-sparing combinations, as well as inflammation-mediating properties distinguish cenicriviroc from first-generation CCR5 antagonists.Based on promising clinical results to date, Tobira initiated a 150-patient Phase llb clinical trial in June 2011 to investigate the antiviral, immunologic and anti‐inflammatory effects of cenicriviroc in HIV‐infected adults. Click Here to read more.